The adenosine pathway in immuno-oncology
Cancer immunotherapy based on immune-checkpoint inhibition or adoptive cell therapy has
revolutionized cancer care. Nevertheless, a large proportion of patients do not benefit from …
revolutionized cancer care. Nevertheless, a large proportion of patients do not benefit from …
Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases
BN Cronstein, M Sitkovsky - Nature Reviews Rheumatology, 2017 - nature.com
Adenosine, a nucleoside derived primarily from the extracellular hydrolysis of adenine
nucleotides, is a potent regulator of inflammation. Adenosine mediates its effects on …
nucleotides, is a potent regulator of inflammation. Adenosine mediates its effects on …
Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation
Macrophages play a relevant role in innate and adaptive immunity depending on the
balance of the stimuli received. From an analytical and functional point of view, macrophage …
balance of the stimuli received. From an analytical and functional point of view, macrophage …
The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Rα) signaling
CJ Ferrante, G Pinhal-Enfield, G Elson, BN Cronstein… - Inflammation, 2013 - Springer
Murine macrophages are activated by interferon-γ (IFN-γ) and/or Toll-like receptor (TLR)
agonists such as bacterial endotoxin (lipopolysaccharide [LPS]) to express an inflammatory …
agonists such as bacterial endotoxin (lipopolysaccharide [LPS]) to express an inflammatory …
Regulation of inflammation by adenosine
G Haskó, B Cronstein - Frontiers in immunology, 2013 - frontiersin.org
Adenosine, a purine nucleoside generated by the dephosphorylation of adenine
nucleotides, is a potent endogenous physiologic and pharmacologic regulator of many …
nucleotides, is a potent endogenous physiologic and pharmacologic regulator of many …
The purinergic system as a pharmacological target for the treatment of immune-mediated inflammatory diseases
Immune-mediated inflammatory diseases (IMIDs) encompass a wide range of seemingly
unrelated conditions, such as multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory …
unrelated conditions, such as multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory …
Regulation of macrophage function by adenosine
Following its release into the extracellular space in response to metabolic disturbances, the
endogenous nucleoside adenosine exerts a range of immunomodulatory effects and cells of …
endogenous nucleoside adenosine exerts a range of immunomodulatory effects and cells of …
Exploiting poly (I: C) to induce cancer cell apoptosis
F Bianchi, S Pretto, E Tagliabue, A Balsari… - Cancer biology & …, 2017 - Taylor & Francis
ABSTRACT TLR3 belong to the Toll-like receptors family, it is mainly expressed on immune
cells where it senses pathogen-associated molecular patterns and initiates innate immune …
cells where it senses pathogen-associated molecular patterns and initiates innate immune …
Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy
SM Hatfield, MV Sitkovsky - The Journal of Clinical …, 2020 - Am Soc Clin Investig
Hypoxia/HIF-1α–and extracellular adenosine/A2 adenosine receptor–mediated
immunosuppression protects tissues from collateral damage by antipathogen immune cells …
immunosuppression protects tissues from collateral damage by antipathogen immune cells …
Toll-like receptor activation and hypoxia use distinct signaling pathways to stabilize hypoxia-inducible factor 1α (HIF1A) and result in differential HIF1A-dependent …
J Jantsch, M Wiese, J Schödel… - Journal of leukocyte …, 2011 - academic.oup.com
ABSTRACT HIF1A is a transcription factor that plays a central role for the adaptation to
tissue hypoxia and for the inflammatory response of myeloid cells, including DCs. HIF1A is …
tissue hypoxia and for the inflammatory response of myeloid cells, including DCs. HIF1A is …